Several PI3K/AKT/ mTOR pathway inhibitors for the treatment of cSCC have been developed and assessed in preclinical and clinical studies (Alzahrani, 2019[8]; De Kort et al., 2021[48]). The gene discussed is MTOR; the disease is skin squamous cell carcinoma.